30
Participants
Start Date
January 27, 2025
Primary Completion Date
March 31, 2026
Study Completion Date
May 31, 2026
AMT-143 hydrogel containing containing ropivacaine
AMT-143 is provided as a hydrogel containing 385 mg/mL ropivacaine (on a ropivacaine HCl equivalence basis). AMT-143 hydrogel will be provided as pre-filled syringes for administration via instillation into the surgical site after surgery and prior to suture.
Ropivacaine
5 mL Ropivacaine 10 mg/mL (1%) solution
Placebo
Saline Placebo
McMaster University, Hamilton
Lead Sponsor
AmacaThera Inc.
INDUSTRY